ArticleEmerging infectious diseases2016
Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.
Article in Emerging infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Identifying the Anti-MERS-CoV and Anti-HcoV-229E Potential Drugs from theMolecules (Basel, Switzerland) · 2023Article
- SARS-CoV-2 reinfection and implications for vaccine development.Human vaccines & immunotherapeutics · 2020Review
- Recent updates on COVID-19: A holistic review.Heliyon · 2020Review
- Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.Vaccine · 2020Review
- Mapping COVID-19 related research from Saudi Arabia, a scoping review. Between reality and dreams.Saudi medical journal · 2020Article
- Article
- Review
- MERS: Progress on the global response, remaining challenges and the way forward.Antiviral research · 2018Review
- Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.Human vaccines & immunotherapeutics · 2018Review
- Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus.Human vaccines & immunotherapeutics · 2017Review
- Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.Human vaccines & immunotherapeutics · 2017Review
- Vaccines for epidemic infections and the role of CEPI.Human vaccines & immunotherapeutics · 2017Review
- Structural insights into the Middle East respiratory syndrome coronavirus 4a protein and its dsRNA binding mechanism.Scientific reports · 2017Article
- A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.Journal of medical microbiology · 2017Review
- New episode of Middle East Respiratory Syndrome Coronavirus outbreak in Saudi Arabia: an emerging public health threat.Public health · 2017Article
- Article
- Development of Recombinant Measles Virus-Based Vaccines.Methods in molecular biology (Clifton, N.J.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Middle East respiratory syndrome (MERS) remains a serious international public health threat. With the goal of accelerating the development of countermeasures against MERS coronavirus (MERS-CoV), funding agencies, nongovernmental organizations, and researchers across the world assembled in Riyadh, Saudi Arabia, on November 14-15, 2015, to discuss vaccine development challenges. The meeting was spearheaded by the Saudi Ministry of Health and co-organized by the International Vaccine Institute, South Korea. Accelerating the development of a preventive vaccine requires a better understanding of MERS epidemiology, transmission, and pathogenesis in humans and animals. A combination of rodent and nonhuman primate models should be considered in evaluating and developing preventive and therapeutic vaccine candidates. Dromedary camels should be considered for the development of veterinary vaccines. Several vaccine technology platforms targeting the MERS-CoV spike protein were discussed. Mechanisms to maximize investment, provide robust data, and affect public health are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.